Physician profile
Michael L Boothe
NPI 1558357079
$1,574.09
in general payments reported to CMS, 2019-2025
25 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $139 · 2021: $199 · 2022: $308 · 2023: $264 · 2024: $374 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $771.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $219.64 | 2021-2024 | |
| Abbvie INC. | $172.62 | 2019-2024 | Liletta, Lo Loestrin Fe |
| Exeltis, USA INC. | $162.85 | 2020-2025 | Slynd |
| Agile Therapeutics, INC. | $134.68 | 2021-2022 | |
| Biogen, INC. | $131.02 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $107.88 | 2020-2022 | |
| Hologic Sales and Service, LLC | $104.08 | 2019-2024 | Aptima |
| Astellas Pharma US INC | $101.17 | 2023-2024 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $62.24 | 2023-2025 | |
| Mylan Pharmaceuticals INC. | $51.32 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $46.78 | 2019-2024 | Gardasil 9, Gardasil |
| Biohaven Pharmaceutical Holding Company Ltd. | $41.23 | 2022 | |
| Aspira Women'S Health INC | $33.07 | 2022-2024 | Ova1 |
| Organon LLC | $25.92 | 2024-2025 | Nexplanon |
| Abbott Laboratories | $24.28 | 2024 | Proclaim |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $22.31 | 2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $20.27 | 2023 | Myfembree |
| Mallinckrodt Enterprises LLC | $17.32 | 2019 | |
| Shield Therapeutics INC | $16.90 | 2024 | |
| Medicem INC. | $15.30 | 2024 | |
| Lupin INC. | $14.20 | 2019 | |
| Olympus America INC. | $14.07 | 2020 | |
| Novo Nordisk INC | $13.85 | 2022 | |
| Minerva Surgical, INC | $12.92 | 2022 | |
| Hologic INC | $8.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Boothe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.